LRMR
Larimar Therapeutics, Inc.
Price Chart
Latest Quote
$3.70
+0.03 (+0.82%)
Current Price
| Previous Close | $3.67 |
| Open | $3.61 |
| Day High | $3.79 |
| Day Low | $3.60 |
| Volume | 1,383,643 |
Stock Information
| Shares Outstanding | 103.88M |
| Total Debt | $3.78M |
| Cash Equivalents | $200.38M |
| Net Income | $-166.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $384.37M |
| EPS (TTM) | $-2.14 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $189.61M |
| Income | $-166.00M |
| Book/sh | $1.51 |
| Cash/sh | $1.93 |
| Employees | 71 |
Financial Ratios
| Quick Ratio | 4.21 |
| Current Ratio | 4.29 |
| Debt/Eq | 2.39 |
Returns & Margins
| ROA | -56.92% |
| ROE | -109.83% |
Ownership
| Insider Ownership | 1.15% |
| Institutional Ownership | 86.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.14 |
| P/B | 2.44 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $14.40 |
Technical Indicators
| SMA20 | $3.59 |
| SMA50 | $3.58 |
| SMA200 | $3.93 |
| RSI | 50.75 |
| ATR | 0.3383 |
| Shares Float | 59.94M |
| Short Float | 18.13% |
| Short Ratio | 4.09 |
| Volatility | 0.84 |
| Rel Volume | 0.45 |
Performance History
| Week | -13.55% |
| Month | +8.82% |
| Quarter | -21.61% |
| 6 Months | +8.50% |
| YTD | +6.63% |
| Year | +15.62% |
| 3 Years | +17.09% |
| 5 Years | -67.49% |
| 10 Years | -95.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $3.70 | 1,389,100 |
| 2026-07-16 | $3.67 | 1,336,100 |
| 2026-07-15 | $3.81 | 1,269,900 |
| 2026-07-14 | $3.72 | 1,841,700 |
| 2026-07-13 | $3.72 | 2,297,800 |
| 2026-07-10 | $4.28 | 3,445,400 |
| 2026-07-09 | $4.13 | 3,823,900 |
| 2026-07-08 | $3.61 | 2,063,900 |
| 2026-07-07 | $3.41 | 1,741,700 |
| 2026-07-06 | $3.29 | 1,750,600 |
| 2026-07-02 | $3.26 | 2,443,400 |
| 2026-07-01 | $3.21 | 2,610,200 |
| 2026-06-30 | $3.05 | 3,199,700 |
| 2026-06-29 | $3.20 | 13,429,900 |
| 2026-06-26 | $3.66 | 9,106,800 |
| 2026-06-25 | $3.50 | 1,774,400 |
| 2026-06-24 | $3.63 | 1,568,800 |
| 2026-06-23 | $3.68 | 1,977,500 |
| 2026-06-22 | $3.66 | 1,852,900 |
| 2026-06-18 | $3.64 | 3,301,200 |
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
đ° Latest News
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Insider Monkey âĸ 2026-07-15T15:43:08Z
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
Stocktwits âĸ 2026-07-08T22:44:35Z
Hereâs What Citi Thinks About Larimar Therapeutics (LRMR)
Insider Monkey âĸ 2026-07-03T13:13:38Z
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
Stocktwits âĸ 2026-07-02T20:32:52Z
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
InvestorsHub âĸ 2026-06-29T14:00:36Z
Larimar's Rare Disease Push Just Hit A Key Inflection Point â What Investors Need To Know
Stocktwits âĸ 2026-06-29T13:02:48Z
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp
MT Newswires âĸ 2026-06-29T12:26:59ZExploring 3 High Growth Tech Stocks in US Market
Simply Wall St. âĸ 2026-06-15T11:39:04Z
Exploring US High Growth Tech Stocks This May 2026
Simply Wall St. âĸ 2026-05-15T11:38:21Z
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
Insider Monkey âĸ 2026-03-27T07:30:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $172,497,000 | $90,890,000 | $41,758,000 | $36,526,000 |
| Other Income Expense | $6,824,000 | $10,286,000 | $4,809,000 | $1,171,000 |
| Other Non Operating Income Expenses | $6,824,000 | $10,286,000 | $4,809,000 | $1,171,000 |
| Operating Expense | $172,497,000 | $90,890,000 | $41,758,000 | $36,526,000 |
| General And Administrative Expense | $18,273,000 | $17,612,000 | $14,088,000 | $12,276,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Normalized Income | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Net Income From Continuing And Discontinued Operation | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Total Operating Income As Reported | $-172,497,000 | $-90,890,000 | $-41,758,000 | $-36,526,000 |
| Net Income Common Stockholders | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Net Income | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Net Income Including Noncontrolling Interests | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Net Income Continuous Operations | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Pretax Income | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Operating Income | $-172,497,000 | $-90,890,000 | $-41,758,000 | $-36,526,000 |
| Per Share | ||||
| Diluted EPS | $-2.27 | $-1.32 | $-0.84 | $-1.37 |
| Basic EPS | $-2.27 | $-1.32 | $-0.84 | $-1.37 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-172,147,000 | $-90,572,000 | $-41,447,000 | $-36,208,000 |
| Reconciled Depreciation | $350,000 | $318,000 | $311,000 | $318,000 |
| EBITDA (Bullshit earnings) | $-172,147,000 | $-90,572,000 | $-41,447,000 | $-36,208,000 |
| EBIT | $-172,497,000 | $-90,890,000 | $-41,758,000 | $-36,526,000 |
| Diluted Average Shares | $72,947,927 | $61,256,084 | $43,901,241 | $25,761,394 |
| Basic Average Shares | $72,947,927 | $61,256,084 | $43,901,241 | $25,761,394 |
| Diluted NI Availto Com Stockholders | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Research And Development | $154,224,000 | $73,278,000 | $27,670,000 | $24,250,000 |
| Selling General And Administration | $18,273,000 | $17,612,000 | $14,088,000 | $12,276,000 |
| Other Gand A | $18,273,000 | $17,612,000 | $14,088,000 | $12,276,000 |
Fetched: 2026-07-07
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Total Assets | $145,842,000 | $200,225,000 | $95,935,000 | $126,405,000 |
| Total Non Current Assets | $3,820,000 | $4,921,000 | $5,760,000 | $5,666,000 |
| Other Non Current Assets | $1,129,000 | $1,202,000 | $1,998,000 | $1,977,000 |
| Current Assets | $142,022,000 | $195,304,000 | $90,175,000 | $120,739,000 |
| Other Current Assets | $253,000 | $517,000 | $377,000 | $238,000 |
| Prepaid Assets | $4,170,000 | $10,279,000 | $2,676,000 | $2,073,000 |
| Receivables | $747,000 | $1,054,000 | $332,000 | $0 |
| Accrued Interest Receivable | $747,000 | $1,054,000 | $332,000 | - |
| Cash Cash Equivalents And Short Term Investments | $136,852,000 | $183,454,000 | $86,790,000 | $118,428,000 |
| Cash And Cash Equivalents | $85,412,000 | $33,218,000 | $26,749,000 | $26,825,000 |
| Cash Equivalents | - | $26,702,000 | $24,701,000 | $22,184,000 |
| Cash Financial | - | $6,516,000 | $2,048,000 | $4,641,000 |
| Taxes Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $4,067,000 | $5,117,000 | $5,546,000 | $5,408,000 |
| Long Term Debt And Capital Lease Obligation | $2,962,000 | $4,057,000 | $4,709,000 | $4,797,000 |
| Current Debt And Capital Lease Obligation | $1,105,000 | $1,060,000 | $837,000 | $611,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $67,757,000 | $28,413,000 | $14,215,000 | $15,502,000 |
| Total Non Current Liabilities Net Minority Interest | $2,962,000 | $4,057,000 | $4,709,000 | $4,797,000 |
| Current Liabilities | $64,795,000 | $24,356,000 | $9,506,000 | $10,705,000 |
| Payables And Accrued Expenses | $63,690,000 | $23,296,000 | $8,669,000 | $10,094,000 |
| Payables | $5,216,000 | $2,424,000 | $1,283,000 | $1,686,000 |
| Accounts Payable | $5,216,000 | $2,424,000 | $1,283,000 | $1,686,000 |
| Equity | ||||
| Common Stock Equity | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Total Equity Gross Minority Interest | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Stockholders Equity | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Gains Losses Not Affecting Retained Earnings | $54,000 | $148,000 | $81,000 | $-31,000 |
| Other Equity Adjustments | $54,000 | $148,000 | $81,000 | $-31,000 |
| Retained Earnings | $-434,831,000 | $-269,158,000 | $-188,554,000 | $-151,605,000 |
| Other | ||||
| Preferred Shares Number | $500,000 | $500,000 | $500,000 | $500,000 |
| Ordinary Shares Number | $83,090,392 | $63,815,065 | $43,909,069 | $43,269,200 |
| Share Issued | $83,090,392 | $63,815,065 | $43,909,069 | $43,269,200 |
| Tangible Book Value | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Invested Capital | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Working Capital | $77,227,000 | $170,948,000 | $80,669,000 | $110,034,000 |
| Capital Lease Obligations | $4,067,000 | $5,117,000 | $5,546,000 | $5,408,000 |
| Total Capitalization | $78,085,000 | $171,812,000 | $81,720,000 | $110,903,000 |
| Additional Paid In Capital | $512,779,000 | $440,758,000 | $270,150,000 | $262,496,000 |
| Capital Stock | $83,000 | $64,000 | $43,000 | $43,000 |
| Common Stock | $83,000 | $64,000 | $43,000 | $43,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,962,000 | $4,057,000 | $4,709,000 | $4,797,000 |
| Current Capital Lease Obligation | $1,105,000 | $1,060,000 | $837,000 | $611,000 |
| Current Accrued Expenses | $58,474,000 | $20,872,000 | $7,386,000 | $8,408,000 |
| Net PPE | $2,691,000 | $3,719,000 | $3,762,000 | $3,689,000 |
| Accumulated Depreciation | $-1,893,000 | $-1,543,000 | $-1,225,000 | $-914,000 |
| Gross PPE | $4,584,000 | $5,262,000 | $4,987,000 | $4,603,000 |
| Leases | $93,000 | $45,000 | $45,000 | $31,000 |
| Other Properties | $3,806,000 | $4,545,000 | $4,270,000 | $4,050,000 |
| Machinery Furniture Equipment | $685,000 | $672,000 | $672,000 | $522,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $51,440,000 | $150,236,000 | $60,041,000 | $91,603,000 |
Fetched: 2026-07-07
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-113,292,000 | $-71,275,000 | $-33,623,000 | $-27,669,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-113,201,000 | $-70,760,000 | $-33,459,000 | $-27,569,000 |
| Cash Flow From Continuing Operating Activities | $-113,201,000 | $-70,760,000 | $-33,459,000 | $-27,569,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-91,000 | $-515,000 | $-164,000 | $-100,000 |
| Investing Cash Flow | $100,309,000 | $-85,387,000 | $33,353,000 | $-90,960,000 |
| Cash Flow From Continuing Investing Activities | $100,309,000 | $-85,387,000 | $33,353,000 | $-90,960,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $65,086,000 | $161,806,000 | $0 | $75,257,000 |
| Financing Cash Flow | $65,086,000 | $161,883,000 | $30,000 | $75,257,000 |
| Cash Flow From Continuing Financing Activities | $65,086,000 | $161,883,000 | $30,000 | $75,257,000 |
| Net Common Stock Issuance | $65,086,000 | $161,806,000 | $0 | $75,257,000 |
| Common Stock Issuance | $65,086,000 | $161,806,000 | $0 | $75,257,000 |
| Other | ||||
| End Cash Position | $86,018,000 | $33,824,000 | $28,088,000 | $28,164,000 |
| Beginning Cash Position | $33,824,000 | $28,088,000 | $28,164,000 | $71,436,000 |
| Changes In Cash | $52,194,000 | $5,736,000 | $-76,000 | $-43,272,000 |
| Proceeds From Stock Option Exercised | $0 | $77,000 | $30,000 | $0 |
| Net Investment Purchase And Sale | $100,400,000 | $-84,872,000 | $33,517,000 | $-90,860,000 |
| Sale Of Investment | $184,000,000 | $143,000,000 | $134,750,000 | $42,750,000 |
| Purchase Of Investment | $-83,600,000 | $-227,872,000 | $-101,233,000 | $-133,610,000 |
| Net PPE Purchase And Sale | $-91,000 | $-515,000 | $-164,000 | $-100,000 |
| Purchase Of PPE | $-91,000 | $-515,000 | $-164,000 | $-100,000 |
| Change In Working Capital | $47,097,000 | $6,175,000 | $-2,511,000 | $1,669,000 |
| Change In Other Current Assets | $73,000 | $63,000 | $-21,000 | $31,000 |
| Change In Payables And Accrued Expense | $40,344,000 | $14,577,000 | $-1,425,000 | $1,842,000 |
| Change In Accrued Expense | $37,552,000 | $13,436,000 | $-1,022,000 | $1,816,000 |
| Change In Payable | $2,792,000 | $1,141,000 | $-403,000 | $26,000 |
| Change In Account Payable | $2,792,000 | $1,141,000 | $-403,000 | $26,000 |
| Change In Prepaid Assets | $6,680,000 | $-8,465,000 | $-1,065,000 | $-204,000 |
| Other Non Cash Items | $-281,000 | $-189,000 | $-82,000 | $-46,000 |
| Stock Based Compensation | $7,004,000 | $8,796,000 | $7,615,000 | $6,619,000 |
| Amortization Of Securities | $-1,698,000 | $-5,256,000 | $-1,843,000 | $-774,000 |
| Depreciation Amortization Depletion | $350,000 | $318,000 | $311,000 | $318,000 |
| Depreciation And Amortization | $350,000 | $318,000 | $311,000 | $318,000 |
| Depreciation | $350,000 | $318,000 | $311,000 | $318,000 |
| Net Income From Continuing Operations | $-165,673,000 | $-80,604,000 | $-36,949,000 | $-35,355,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
Fetched: 2026-07-07